I started GLP-1 at 47, just before the hormonal changes of perimenopause began making themselves known. I’ve talked to enough women over 50 using GLP-1 to know that the experience is similar in many ways but has specific differences worth understanding before you start.
The medication works the same way regardless of age. What changes is the body it’s working in.
Why Weight Loss Is Harder After 50
This isn’t in anyone’s head. Specific biological changes make weight loss genuinely harder after menopause:
Estrogen decline changes fat distribution. Before menopause, estrogen directs fat storage toward the hips and thighs. After menopause, that pattern shifts toward visceral fat — the fat stored around the abdominal organs. Visceral fat is more metabolically active and more resistant to standard diet interventions than subcutaneous fat.
Metabolic rate slows with age. Resting metabolic rate — how many calories you burn doing nothing — decreases with age, partly because of muscle loss and partly because of hormonal changes. The same caloric intake that maintained weight at 40 produces weight gain at 55 in many women.
Muscle loss accelerates after menopause. Estrogen plays a role in muscle preservation. After menopause, the rate of muscle loss (sarcopenia) increases. Less muscle means lower metabolic rate and reduced capacity for the exercise that supports weight loss.
Insulin sensitivity decreases. Postmenopausal women tend toward lower insulin sensitivity, which affects how the body processes carbohydrates and stores fat.
GLP-1 medications address several of these mechanisms directly — appetite suppression, blood sugar regulation, and visceral fat reduction are all documented effects. But the starting point is different, and the results reflect that.
What GLP-1 Research Shows for Older Women
Clinical trials for semaglutide have included women over 50, and the results are meaningful but different from the headline numbers. The large STEP trials showed average weight loss of 14 to 17 percent of body weight over 68 weeks. In subgroup analyses, older participants and postmenopausal women tended to show somewhat less weight loss than the overall average — typically in the 10 to 13 percent range.
Ten to thirteen percent of body weight is still significant. For a woman starting at 200 pounds, that’s 20 to 26 pounds. That’s real change in health markers, mobility, joint pain, and metabolic function.
The expectation adjustment: if you’re over 50 and comparing your results to a 35-year-old’s testimonial, you’re probably comparing to the wrong benchmark.
Muscle Loss: The Most Important Factor to Manage
Because postmenopausal women are already at higher risk for muscle loss, the additional muscle loss that comes with GLP-1’s rapid weight reduction is more significant in this population than in younger women.
This makes resistance training and adequate protein intake not optional but essential for women over 50 on GLP-1. The goal isn’t just to lose weight — it’s to ensure what you lose is primarily fat, not the muscle mass you’re already at risk of losing through aging.
Two strength training sessions per week, protein intake of 100 grams or more per day, and creatine supplementation are the evidence-backed interventions for this. At 47, these were recommendations from my provider from day one. For women over 50, they’re even more important.
Menopause Symptoms and GLP-1
An area of emerging research and significant anecdotal discussion: some women report that GLP-1 therapy affects menopause symptoms. Hot flashes, sleep quality, and mood are the most commonly mentioned areas.
The evidence here is early and not definitive. GLP-1 affects inflammatory pathways and metabolic function broadly, and some of these effects may interact with menopause symptoms. Weight loss itself improves hot flash frequency and severity in many women — so separating the medication’s direct effect from the weight loss effect is difficult.
If you’re experiencing menopause symptoms alongside weight struggles, GLP-1 isn’t a menopause treatment — but the weight loss it produces may provide some symptom relief as a secondary effect.
NAD+ and Energy After 50
One of the most significant challenges for women over 50 on GLP-1 is energy. The combination of reduced caloric intake, age-related decline in cellular energy production, and the hormonal changes of menopause creates a fatigue picture that can make exercise feel impossible.
NAD+ levels decline significantly with age — more so after menopause. NAD+ is involved in cellular energy production at the mitochondrial level. NAD+ therapy is worth discussing with your provider if energy is a significant limiting factor in your exercise capacity.
I added NAD+ in month five and noticed a meaningful difference in afternoon energy within three to four weeks. For women over 50, NAD+ depletion is more advanced than in younger populations, which may mean the response is more pronounced.
The NAD+ program I use is here.
Affiliate link — I may earn a commission at no extra cost to you.
Starting GLP-1 After 50
The process for accessing GLP-1 after 50 is the same as at any age — telehealth is the fastest path for women without insurance coverage. Compounded semaglutide through a licensed provider runs $200 to $400 per month.
The expectations calibration is worth doing before you start: results in this age group are real and meaningful, and slower than what you’ll see in younger populations. That’s not a reason not to start. It’s a reason to start with accurate information.
The GLP-1 program I use is here.
Affiliate link — I may earn a commission at no extra cost to you.